|Bid||232.77 x 900|
|Ask||233.82 x 900|
|Day's Range||228.31 - 238.68|
|52 Week Range||6.77 - 331.68|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||253.75|
Less than a year before the Covid-19 pandemic ravaged the world, Novavax was facing delisting from the Nasdaq. The pharmaceutical company had poured hundreds of millions of dollars into research and development for vaccines — and yet, at 33 years old, was approaching middle age without a single approved shot. Interim data have shown that its vaccine has an efficacy rate up there with the shots developed by BioNTech/Pfizer and Moderna, based on revolutionary messengerRNA technology.
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]
Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine was given an emergency use authorization (EAU) Saturday evening by U.S. Food and Drug Administration (FDA), making it the third vaccine available in the U.S.